Early translation and proof of mechanism

Our fully integrated approach to drug development includes working closely with colleagues in cancer genetics and genomics, cancer immunology, cancer therapeutics, organogenesis, tumour angiogenesis and clinical research, allowing us to take novel therapies into first-in-human trials

Molecular imaging 

  • 6000 PET scans per annum 

  • Nuclear medicine specialists 

  • FDG, FLT, FCH, FET, Novel tracers 


  • Tissue 

  • Plasma/Serum 

  • IHC, DNA, RNA, Protein 

  • ctDNA 

Molecular pathology 

  • NATA ISO 15189:2012 accreditation 

  • Defined mutations or polymorphism testing 

  • Pharmacogenetic testing 

  • Screening for unknown mutations 

Cell therapies 

  • GMP cell production facility 

  • Gene therapy 

Human immunology and translational research laboratory 

  • Immune biomarkers 

  • Mouse models 

  • Clinical trial supportive studies